about
Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza VirusesConsiderations for the rapid deployment of vaccines against H7N9 influenza.Establishment of functional influenza virus-specific CD8(+) T cell memory pools after intramuscular immunization.A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individualsHepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responsesGeneration of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2CysInactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.Structure-function relationships of protein-lipopeptide complexes and influence on immunogenicity.PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+ T cell responses.A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year.Reducing the impact of influenza-associated secondary pneumococcal infections.The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses.Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus.Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys.Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2.Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.Dendritic cell acquisition of epitope cargo mediated by simple cationic peptide structures.Control of size dispersity of chitosan biopolymer microparticles and nanoparticles to influence vaccine trafficking and cell uptake.Opinion: Making Inactivated and Subunit-Based Vaccines Work.Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups.Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists.Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.Electrostatic-mediated enhancement of protein antigen immunogenicity using charged TLR2-targeting lipopeptidesChitosan Microparticles and Nanoparticles as Biocompatible Delivery Vehicles for Peptide and Protein-Based Immunocontraceptive VaccinesThe Toll-Like Receptor 2 agonist PEG-PamCys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasitesHuman CD8+ T cell cross-reactivity across influenza A, B and C virusesRecalling the Future: Immunological Memory Toward Unpredictable Influenza VirusesGeometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response
P50
Q28548477-C6F9A137-EE8B-4D08-AF24-9F8C74DBBDCDQ30364635-8B60A189-F73D-4F25-96F1-686C5E20C5EAQ30377948-85A82120-A090-45E7-B805-C6712AC1A138Q34091925-5BF4D18C-4B74-42FB-BDCD-CFC274E3C618Q34455275-69F5A222-45BD-47F2-9993-C1464DFEE6DEQ35687079-C763C734-5A8D-4F94-B6E5-16F04B13CDB0Q36227268-99FBD85E-2F8E-45BC-8FA9-E52E5AB17A20Q40130682-9065DDE9-4BF5-402F-AE9B-9699B2E1EDDAQ40198556-62F94142-FADB-4512-97B2-CAA361267DEAQ41044483-2186E932-DEE4-4239-8DAC-4B8C2BC0556FQ41128275-B2F7FB48-CFCD-4830-9C71-6052FB558D65Q42244917-822ED273-0FD8-4C0A-954C-607A581A58EBQ43041894-AEF44F06-A07F-47E2-ABDC-3A15C16A3950Q43187563-569C3DE2-FA9E-4793-B0A4-3BAB5655C2DDQ44109738-9F04339D-0245-42AB-80A7-4125D5C53774Q46411811-6A18D5D7-790C-4A5A-814F-8A9DE9465454Q46672767-8623C7AF-C6FA-448E-A5B3-02DD7EC9C384Q47316700-D42F4769-ACD7-4807-8B2A-1522857AC6F2Q47548968-A325BA64-D9A2-4A88-84BB-30C9FF4E451DQ51779423-649CA6A0-7566-4BDF-B175-73B0CB4D9F6AQ54265038-AEB3A168-55DE-47E4-9417-5DBEB8208C23Q55303632-E7FD232B-CC0C-4E85-B236-B98F5611F91BQ57082181-370CD306-4B16-443C-919D-DC9005BF87ABQ57607747-4F52D932-E25F-4884-813B-9047FA985559Q58574880-2D88AF4A-B460-4E8D-A216-AFD4FE699421Q91692073-F0713F83-447C-4361-99EB-12B924DB22F1Q91938950-7590EB0F-5382-423B-9D33-0EF1979B7D49Q92696180-33BD0159-0C5D-4235-95DF-CB9FFFC830E7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Brendon Chua
@ast
Brendon Chua
@en
Brendon Chua
@es
Brendon Chua
@nl
Brendon Chua
@sl
type
label
Brendon Chua
@ast
Brendon Chua
@en
Brendon Chua
@es
Brendon Chua
@nl
Brendon Chua
@sl
prefLabel
Brendon Chua
@ast
Brendon Chua
@en
Brendon Chua
@es
Brendon Chua
@nl
Brendon Chua
@sl
P1053
A-9755-2012
P106
P1153
13004005700
P21
P31
P3829
P496
0000-0001-5654-1293
P569
2000-01-01T00:00:00Z